Veristat Expands Regulatory and Clinical Trial Support for Chinese Pharmaceutical and Medical Device Companies Entering Global Markets
Veristat, a global contract research organization (CRO) and consulting firm known for its expertise in complex clinical trials, has announced the expansion of its regulatory and clinical trial services for international pharmaceutical and medical device companies aiming to enter major global markets. The expanded services are designed to help companies navigate regulatory pathways and accelerate market entry in regions including Europe, the United Kingdom, Switzerland, Australia, Canada, and the United States.
The expansion reflects a growing demand from pharmaceutical and biotechnology companies—particularly those based in China—that are increasingly seeking opportunities to commercialize their products internationally. As global competition intensifies and regulatory environments become more complex, organizations are looking for experienced partners capable of guiding them through the approval process efficiently and effectively.
Rising Global Ambitions of Chinese Pharma
China has emerged as the world’s second-largest pharmaceutical producer. Historically, many Chinese pharmaceutical and biotechnology companies focused primarily on domestic markets. However, this trend is rapidly changing as Chinese drug developers expand their global ambitions.
Today, a significant portion of innovative drug research originates in China. Industry estimates suggest that nearly half of the new drug molecules currently in human clinical trials worldwide are developed by Chinese organizations. As these innovations continue to grow, analysts expect the global influence of Chinese pharmaceutical companies to increase significantly in the coming years.
Financial projections highlight this shift. According to research cited by global financial institutions such as Morgan Stanley, annual sales from Chinese-origin drugs could reach approximately $34 billion by 2030 and potentially climb to $220 billion by 2040. These forecasts reflect increasing international partnerships, licensing deals, and regulatory approvals for innovative treatments developed in China.
Recent policy changes within China have also created new opportunities for pharmaceutical companies to expand overseas. The country is increasingly becoming a hub for international licensing agreements, allowing pharmaceutical developers to collaborate with global partners to commercialize products in foreign markets. However, despite the growing pipeline of innovative therapies, many Chinese companies still face challenges when navigating regulatory systems outside their home country.
Overcoming Regulatory and Development Challenges
Entering global markets such as Europe and the United States requires meeting strict regulatory standards. Pharmaceutical companies must demonstrate the safety, efficacy, and quality of their products through extensive documentation and clinical data. In some cases, clinical trial data generated in China may not fully align with the requirements of regulatory agencies in other regions.
This is where organizations like Veristat play a critical role. The company provides regulatory strategy, consulting, and clinical trial support to pharmaceutical and medical device companies seeking approvals outside their domestic markets. Through its services, Veristat helps clients navigate the complex regulatory frameworks required for market authorization.
The company has already supported several Chinese pharmaceutical companies in obtaining regulatory approvals abroad, including collaborations with firms such as Hansoh Pharma and CStone Pharmaceuticals. By assisting these organizations with regulatory submissions and compliance requirements, Veristat has helped accelerate their progress toward international commercialization.
Comprehensive Regulatory Services
Veristat offers a broad range of regulatory services designed to simplify the approval process for international clients. These services include preparing and submitting regulatory applications, developing strategic approval pathways, and ensuring compliance with regional guidelines.
A major part of the company’s work involves preparing complex regulatory submissions such as Marketing Authorization Applications (MAAs) and New Drug Applications (NDAs). These submissions are required by regulatory authorities before a new therapy can be marketed in many countries. Veristat’s experience in compiling and managing regulatory dossiers enables companies to present their clinical and scientific data effectively to regulatory agencies.
In addition, Veristat can act as a regulatory applicant on behalf of companies that do not yet have a legal presence in specific regions. This service allows international pharmaceutical developers to submit regulatory applications and begin the approval process without establishing immediate local infrastructure.
Data Analysis and Regulatory Strategy
A key step in the regulatory process involves evaluating the existing clinical data generated during product development. Veristat’s multidisciplinary team conducts detailed gap analyses of each client’s data package to identify whether additional studies or analyses are needed to satisfy regulatory requirements in target markets.
Based on this assessment, the team develops tailored regulatory strategies for each region. These strategies outline the most efficient pathway to approval, helping companies avoid unnecessary delays and optimize their submission timelines. When additional clinical data is required, Veristat also provides support in designing and conducting supplementary clinical trials.
For companies whose domestic clinical trial data does not fully meet international regulatory standards, the organization offers comprehensive clinical trial services. These services ensure that additional studies are conducted in compliance with local regulations and scientific best practices.
Collaboration With Global Regulatory Authorities
Successfully bringing a new therapy to international markets often involves direct engagement with regulatory agencies. Veristat has extensive experience working with major regulatory authorities, including the European Medicines Agency, the Medicines and Healthcare products Regulatory Agency in the United Kingdom, and the U.S. Food and Drug Administration.
According to company executives, Veristat recently achieved significant success by helping a China-based client secure regulatory approvals across multiple regions, including the United States, the European Union, and the United Kingdom. These approvals were made possible through comprehensive dossier development and strategic negotiations with regulatory authorities.
The company has also assisted clients with follow-on applications in additional markets such as Canada, Switzerland, and Australia. By managing the regulatory process from submission through review, Veristat ensures that pharmaceutical developers receive consistent guidance throughout each stage of market entry.
A Strong Track Record in Regulatory Approvals
Between 2020 and 2025, Veristat submitted dozens of regulatory applications across multiple jurisdictions. These submissions included 68 initial Investigational New Drug (IND) applications and Drug Master Files (DMFs), as well as 10 initial marketing authorization applications to the U.S. Food and Drug Administration.
The company also submitted eight initial marketing authorization applications to European regulatory agencies including the European Medicines Agency, the Medicines and Healthcare products Regulatory Agency, and Swissmedic, Switzerland’s national regulatory authority for therapeutic products.
With more than three decades of industry experience, Veristat has supported over 100 regulatory approvals worldwide. The organization has particular expertise in complex therapeutic areas such as rare diseases, neurology, oncology, and advanced medical technologies including cell and gene therapies.
Supporting the Future of Global Drug Development
As pharmaceutical innovation continues to expand globally, the need for experienced regulatory and clinical development partners is expected to grow. Chinese pharmaceutical companies, in particular, are increasingly seeking international opportunities to bring their therapies to patients around the world.
By expanding its regulatory and clinical trial services, Veristat aims to help these organizations overcome regulatory barriers and accelerate access to global healthcare markets. With strong experience in navigating international regulatory systems, the company is positioning itself as a key partner for pharmaceutical and medical device companies pursuing worldwide commercialization.
Source link :https://www.businesswire.com/
